Discover if this is a suitable investor for your startup. If they are we'll make a warm introduction for free. Otherwise, we'll connect you with matching investors.
Ascenta Capital is a biotechnology investment firm founded in 2023 by former Moderna executives Evan Rachlin and Lorence Kim. The firm is headquartered in the United States and manages assets totaling $335 million. Ascenta Capital focuses on making concentrated investments in biotech companies, particularly those transitioning from preclinical science to early human safety and efficacy data.
Since its inception, Ascenta Capital has established itself as a key player in the biotech investment landscape. The firm emphasizes a patient-centered approach, prioritizing innovations that can significantly impact patients' lives. Ascenta Capital's team has collectively played critical roles in the development of over 30 approved medicines, showcasing their extensive experience in the sector.
Ascenta Capital's portfolio currently includes eight companies, reflecting its commitment to supporting innovative solutions in healthcare. The firm is dedicated to addressing complex growth and strategy challenges within the biotech sector, making it a notable partner for early-stage companies.
Ascenta Capital targets biotechnology companies in the early stages of development, specifically those in Phase 1 and 2 clinical trials. The firm emphasizes a patient-centered approach, prioritizing innovations that can significantly impact patients' lives. Their investment strategy includes supporting multi-medicine platforms and addressing complex growth and strategy challenges within the biotech sector.
The firm typically invests in pre-seed, seed, and Series A stages, with a focus on companies that are transitioning from preclinical science to early human safety and efficacy data. Ascenta Capital seeks to balance risk through diversified pipelines, investing in companies that are at the nexus of early clinical development and multi-medicine therapeutic platforms.
Ascenta Capital's portfolio includes several notable companies:
These companies represent Ascenta Capital's commitment to advancing innovative solutions in the biotech sector, with a focus on addressing significant medical needs.
Evan Rachlin, MD - Co-Founder and Managing Partner. Previously at Blackstone Life Sciences, he guided strategy at Moderna.
Lorence Kim, MD - Co-Founder and Managing Partner. Former Partner at Third Rock Ventures and CFO of Moderna.
Jeff Chodakewitz, MD - Advisory Partner. Brings extensive experience in clinical development and regulatory strategy.
Michael Rosenblatt, MD - Advisory Partner. Former Chief Medical Officer at Merck, with a focus on drug development.
Paul Deutsch, MD/PhD - Advisory Partner. Expert in clinical research and development with a strong background in biotech.
Daniel Bloomfield, MD - Advisory Partner. Specializes in early-stage biotech investments and clinical strategy.
John Gutierrez, MD - Principal. Focuses on investment analysis and portfolio management.
Leighanne Oh, MS - Vice President. Experienced in operational support and strategic planning.
Dave Shields - Chief Financial Officer. Oversees financial operations and fund management.
Tami Daelen - Chief of Staff. Manages day-to-day operations and team coordination.
Nancy McAdams - Executive Assistant. Provides administrative support to the leadership team.
To pitch to Ascenta Capital, founders should use the contact information provided on their website or email info@ascentacap.com. It is essential to include a comprehensive business plan, details about the team, and information on the technology being developed. Ascenta Capital appreciates well-structured decks that clearly outline the innovation's potential impact on patient care.
Response times may vary, but founders can expect to hear back within a few weeks. Warm introductions are preferred, as they can facilitate a more favorable review process.
In October 2025, Ascenta Capital announced the final close of its inaugural fund, raising $325 million to support early-stage biotech companies. This milestone was covered by major outlets including BusinessWire and FierceBiotech.
As of January 2026, Ascenta Capital has deployed over $100 million into six portfolio companies, demonstrating its active management and commitment to supporting innovative biotech solutions.
Ascenta Capital is attending the BIO Investment & Growth Summit in 2026, further establishing its presence in the biotech investment community.
What are Ascenta Capital's investment criteria?
Ascenta Capital invests in early-stage biotechnology companies, specifically those in Phase 1 and 2 clinical trials. The firm focuses on companies that are transitioning from preclinical science to early human safety and efficacy data.
How can I apply or pitch to Ascenta Capital?
Founders can pitch to Ascenta Capital through their website at ascentacap.com or by emailing info@ascentacap.com. It is recommended to include a detailed business plan and information about the team and technology.
What makes Ascenta Capital different from other investors?
Ascenta Capital's focus on early-stage biotech investments and their patient-centered approach distinguish them from other investors. The firm emphasizes concentrated investments in companies addressing complex challenges within the biotech landscape.
What is the geographic scope of Ascenta Capital's investments?
The firm primarily invests in biotechnology companies based in the United States, focusing on those that align with their investment strategy.
What kind of post-investment involvement does Ascenta Capital have?
Ascenta Capital adds value to its portfolio companies by providing strategic guidance, operational support, and access to a network of industry experts to help navigate the complexities of biotech development.
What is the typical check size for investments made by Ascenta Capital?
While specific check sizes are not disclosed, Ascenta Capital focuses on concentrated investments in early-stage biotech companies, indicating a preference for significant financial commitments to support their portfolio companies.
All trademarks, logos and brand names are the property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, trademarks, and brands does not imply endorsement.